Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irradiated allogeneic lymphocytes
- Development stage
- Unknown
- Lead developer
- Rutgers Cancer Institute
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Irradiated allogeneic lymphocytes is an investigational cell-based immunotherapy developed by Rutgers, The State University of New Jersey, for the treatment of metastatic renal cell carcinoma. The therapy consists of partially HLA-matched blood mononuclear cells (lymphocytes) obtained from relatives of the patient. These cells are irradiated prior to infusion to prevent graft-versus-host disease (GVHD) while retaining their ability to induce an allogeneic immune response against the tumor. This mechanism mimics the graft-versus-tumor (GVT) effect observed in hematopoietic stem cell transplantation but is administered as a standalone biologic therapy. It has been evaluated in Phase II clinical trials (such as the SPECIAL trial) in combination with the tyrosine kinase inhibitor sunitinib for patients with metastatic clear cell renal cell carcinoma.
- Other names
- therapeutic allogeneic lymphocytesirradiated donor lymphocytesirradiated allogeneic blood mononuclear cells
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on irradiated allogeneic lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irradiated allogeneic lymphocytes.